Cogent Biosciences (COGT) is moving higher as investors react to a key regulatory step for its lead asset, bezuclastinib. On April 1, 2026, Cogent announced it submitted a New Drug Application (NDA) to the FDA seeking approval of bezuclastinib for patients with gastrointestinal stromal tumors (GIST) previously treated with imatinib, a development that can pull the story into a more defined regulatory timeline and refocus attention on near-term FDA interactions.

For biotechs nearing commercialization, an NDA submission can function as a de-risking event that draws incremental generalist capital and increases sensitivity to regulatory headlines. Cogent’s GIST filing is also tied to the FDA’s Real-Time Oncology Review (RTOR) framework, which can compress parts of the review workflow and heighten investor focus on incremental FDA updates as they occur. The market is also weighing Cogent’s broader 2026 program cadence, including additional bezuclastinib filings the company has guided for the first half of 2026.

The next catalysts are procedural but market-moving: FDA acknowledgment/acceptance and timing details for the GIST application, plus any commentary on review pathway or data package. Separately, Cogent has already disclosed an FDA acceptance for its NonAdvanced systemic mastocytosis NDA with a PDUFA target action date of December 30, 2026, keeping the stock highly headline-driven as multiple bezuclastinib indications progress in parallel.